NEHI puts a price on patients not adhering to treatment. It’s $290 Billion worth of a new problem for the pharmaceuticals industry – getting beyond the pill to influence the behaviours or patients and thereby influence the outcomes on which their reimbursements, and ultimately profitability, depends. Investment in patient access and adherence technology and programs is set to increase exponential…
Most Popular Content on DSC
To not miss this type of content in the future, subscribe to our newsletter.
Other popular resources
Most popular articles